Leonid Timashev
Stock Analyst at RBC Capital
(4.11)
# 493
Out of 5,132 analysts
148
Total ratings
53.03%
Success rate
12.47%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Sector Perform | $45 → $46 | $43.92 | +4.74% | 3 | Feb 11, 2026 | |
| CMPS COMPASS Pathways | Maintains: Outperform | $16 → $21 | $5.81 | +261.45% | 5 | Jan 23, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $41 → $45 | $30.27 | +48.66% | 4 | Jan 21, 2026 | |
| CYTK Cytokinetics | Reiterates: Outperform | $95 | $66.26 | +43.37% | 6 | Jan 21, 2026 | |
| CGON CG Oncology | Maintains: Outperform | $61 → $73 | $51.50 | +41.75% | 3 | Jan 21, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $219 | $181.21 | +20.85% | 15 | Jan 21, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $44 → $47 | $34.63 | +35.72% | 9 | Jan 21, 2026 | |
| NUVB Nuvation Bio | Maintains: Outperform | $9 → $12 | $5.77 | +107.97% | 4 | Jan 21, 2026 | |
| CRMD CorMedix | Maintains: Outperform | $22 → $13 | $7.34 | +77.11% | 3 | Jan 21, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $140 | $96.31 | +45.36% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $197 → $200 | $148.75 | +34.45% | 8 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $9 → $22 | $11.36 | +93.66% | 14 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 | $17.58 | +275.43% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.30 | +284.62% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $13 | $10.07 | +29.10% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $395 → $408 | $345.95 | +17.94% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $194 | $166.27 | +16.68% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.14 | +250.88% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $30.01 | +66.61% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $11.60 | +63.79% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $27 → $11 | $5.24 | +109.92% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $47 | $33.16 | +41.74% | 5 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.82 | +123.37% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.99 | +25.31% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $4.70 | +240.43% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.73 | +311.58% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $101.10 | -30.76% | 1 | Jan 23, 2025 |
Exelixis
Feb 11, 2026
Maintains: Sector Perform
Price Target: $45 → $46
Current: $43.92
Upside: +4.74%
COMPASS Pathways
Jan 23, 2026
Maintains: Outperform
Price Target: $16 → $21
Current: $5.81
Upside: +261.45%
IDEAYA Biosciences
Jan 21, 2026
Maintains: Outperform
Price Target: $41 → $45
Current: $30.27
Upside: +48.66%
Cytokinetics
Jan 21, 2026
Reiterates: Outperform
Price Target: $95
Current: $66.26
Upside: +43.37%
CG Oncology
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $51.50
Upside: +41.75%
Axsome Therapeutics
Jan 21, 2026
Maintains: Outperform
Price Target: $212 → $219
Current: $181.21
Upside: +20.85%
NewAmsterdam Pharma Company
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $34.63
Upside: +35.72%
Nuvation Bio
Jan 21, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $5.77
Upside: +107.97%
CorMedix
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $7.34
Upside: +77.11%
Revolution Medicines
Jan 21, 2026
Maintains: Outperform
Price Target: $77 → $140
Current: $96.31
Upside: +45.36%
Jan 21, 2026
Maintains: Outperform
Price Target: $197 → $200
Current: $148.75
Upside: +34.45%
Jan 21, 2026
Upgrades: Outperform
Price Target: $9 → $22
Current: $11.36
Upside: +93.66%
Jan 20, 2026
Maintains: Outperform
Price Target: $66
Current: $17.58
Upside: +275.43%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.30
Upside: +284.62%
Nov 20, 2025
Upgrades: Outperform
Price Target: $6 → $13
Current: $10.07
Upside: +29.10%
Nov 18, 2025
Maintains: Outperform
Price Target: $395 → $408
Current: $345.95
Upside: +17.94%
Nov 17, 2025
Maintains: Outperform
Price Target: $155 → $194
Current: $166.27
Upside: +16.68%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.14
Upside: +250.88%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $30.01
Upside: +66.61%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $11.60
Upside: +63.79%
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $5.24
Upside: +109.92%
Oct 23, 2025
Maintains: Outperform
Price Target: $45 → $47
Current: $33.16
Upside: +41.74%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $5.82
Upside: +123.37%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.99
Upside: +25.31%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $4.70
Upside: +240.43%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.73
Upside: +311.58%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $101.10
Upside: -30.76%